| Recruiting | 4 | 1000 | US | Upadacitinib, Rinvoq, Abatacept, Orencia SQ, Secukinumab, Cosentyx, Tofacitinib, Xeljanz, TNF Inhibitor, Etanercept, Certolizumab, Golimumab SQ, Adalimumab, Canakinumab Injection, Ilaris, Baricitinib, Olumiant, Ixekizumab, Taltz | Jeffrey Curtis, University of Alabama at Birmingham, University of Nebraska, University of Pennsylvania, AbbVie, Bristol-Myers Squibb, Novartis, Eli Lilly and Company, Pfizer, Illumination Health | Rheumatoid Arthritis, Psoriatic Arthritis, Spondylarthritis | 02/24 | 09/24 | | |
| Active, not recruiting | 4 | 129 | US | Hepatitis A vaccine, Havrix, Diphtheria, pertussis, and tetanus booster vaccine, Boostrix | Oregon Health and Science University | Rheumatic Diseases | 01/25 | 12/25 | | |
| Recruiting | 4 | 1300 | US | Baricitinib, LY3009104, TNF Inhibitor, Etanercept, Adalimumab | Eli Lilly and Company, Incyte Corporation | Rheumatoid Arthritis | 12/24 | 02/26 | | |
REPLENISH, NCT05767034: Phase III Study of Efficacy and Safety of Secukinumab Versus Placebo, in Combination With Glucocorticoid Taper Regimen, in Patients With Polymyalgia Rheumatica (PMR) |
|
|
| Active, not recruiting | 3 | 381 | Europe, Canada, Japan, US, RoW | Secukinumab 300 mg, AIN457, Secukinumab 150 mg, Placebo to secukinumab | Novartis Pharmaceuticals | Polymyalgia Rheumatica | 09/25 | 02/26 | | |
